| Levin, Myron J |
| Terminated | 4 | 10 | US | bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Biktarvy, Standard initiation of antiretroviral therapy (ART), Standard of Care ART | University of Colorado, Denver, Gilead Sciences | HIV/AIDS | 07/23 | 07/23 | | |
| Completed | 3 | 5197 | Europe, US | AZD7442, Combination of 2mAbs(AZD8895 and AZD1061), Placebo | AstraZeneca, Iqvia Pty Ltd | COVID-19 | 08/22 | 12/23 | | |
|
|
| Recruiting | 3 | 132 | US | Shingrix | University of Colorado, Denver | Kidney Transplant Recipient Response to Shingrix Vaccine | 01/26 | 09/26 | | |
| Recruiting | 2 | 55 | US | Zoster Vaccine Recombinant, Shingrix | University of Colorado, Denver, GlaxoSmithKline | Bone Marrow Transplant, Stem Cell Transplant | 05/25 | 12/30 | | |
| Muramoto, Myra L |
NCT05641974: Effect of Helpers Program On-line Training on Smoking Relapse and Social Networks |
|
|
| Enrolling by invitation | N/A | 940 | US | Helpers Stay Quit Training | University of Colorado, Denver, National Cancer Institute (NCI) | Smoking, Cigarette Smoking | 06/26 | 02/27 | | |
| Rasouli, Neda |
SIB, NCT04979130: Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 42 | US | Semaglutide, Ozempic, PDS290 pen-injector, Placebo | University of Colorado, Denver, Novo Nordisk A/S | Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability | 12/23 | 12/23 | | |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 795 | US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, T2D | 07/24 | 07/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05166382: Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications |
|
|
| Active, not recruiting | N/A | 350 | US | Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D), Informed, Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D), Uninformed | University of Colorado, Denver, SomaLogic, Inc. | Type 2 Diabetes, Cardiovascular Diseases | 01/24 | 01/24 | | |
| Recruiting | N/A | 2000 | US | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases | 09/30 | 09/30 | | |
| Santos, Peter W |
| Terminated | 3 | 270 | Europe, Japan, US, RoW | Bardoxolone methyl, RTA 402 | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc. | Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney | 08/23 | 08/23 | | |
| Terminated | 3 | 667 | Europe, Japan, US, RoW | Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC | Autosomal Dominant Polycystic Kidney, ADPKD | 08/23 | 08/23 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
NCT04557462 / 2020-002200-40: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
|
|
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | LNP023, iptacopan | Novartis Pharmaceuticals, Novartis Pharma AG | Primary IgA Nephropathy | 10/32 | 10/32 | | |
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria |
|
|
| Recruiting | 2 | 60 | US | Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Mineralys Therapeutics Inc. | Chronic Kidney Disease | 02/25 | 05/25 | | |
| Hutchison, Kent E |
| Recruiting | 2/3 | 180 | US | Cannabidiol, Placebo | University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 04/27 | 04/27 | | |
| Completed | 2 | 45 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver | Alcohol Use Disorder | 05/23 | 05/23 | | |
NCT05632627: Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial |
|
|
| Recruiting | 2 | 120 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver, Colorado State University | Brain Injuries, Traumatic | 12/25 | 12/25 | | |
| Recruiting | 2 | 150 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver | Opioid Use Disorder | 02/27 | 02/27 | | |
| Stitt, Jenny |
NCT04774315: Molecular Endotypes of Chronic Idiopathic Urticaria |
|
|
| Active, not recruiting | 4 | 15 | US | Omalizumab | University of Colorado, Denver | Chronic Urticaria, Idiopathic | 03/25 | 03/25 | | |
| Bergman, Bryan |
NCT06129110: Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling |
|
|
| Recruiting | N/A | 70 | US | Diet Weight Loss | University of Colorado, Denver, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity, Insulin Sensitivity, Muscle Weakness, Adiposity, Insulin Resistance | 12/28 | 12/29 | | |
MERIT, NCT06297980: Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes |
|
|
| Recruiting | N/A | 150 | US | Personalized modifications to treatment to address menstrual cycle effects on glycemia | University of Colorado, Denver, The Leona M. and Harry B. Helmsley Charitable Trust | Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances | 10/26 | 10/26 | | |
| Reece, Brett |
| Recruiting | 2/3 | 200 | US | Human platelets | Cellphire Therapeutics, Inc., U.S. Army Medical Research and Development Command | Cardiac Surgery | 01/25 | 02/25 | | |
| Recruiting | N/A | 110 | US, RoW | NEXUS Aortic Stent Graft System | Endospan Ltd. | Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer | 11/24 | 10/29 | | |
| Active, not recruiting | N/A | 115 | US | AMDS | Artivion Inc., Syneos Health | Acute Aortic Dissection | 12/23 | 12/29 | | |
| Recruiting | N/A | 2000 | Europe, Canada, US | Gelsoft Plus Vascular Graft, Gelsoft Plus, Vascular Bypass Graft, Gelsoft Plus Extra Anatomical, Cardiovascular Patch, Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics, Gelweave Vascular Graft, Gelweave, Gelweave Valsalva Vascular Graft, Gelweave Valsalva | Vascutek Ltd. | Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases | 01/26 | 01/33 | | |
| Recruiting | N/A | 1100 | US | TEVAR, Guideline directed medical therapy and surveillance of dissection | Duke University, The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI) | Type B Aortic Dissection | 06/30 | 06/30 | | |
| Miravalle, Augusto |
NCT05671055: CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis |
|
|
| Completed | N/A | 300 | Europe, US | Custom study version of icompanion app | icometrix, Bristol-Myers Squibb | Multiple Sclerosis | 12/23 | 12/23 | | |
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS |
|
|
| Active, not recruiting | N/A | 295 | US | Cladribine Tablets | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 05/25 | 05/25 | | |
| Jacobs, Donald |
| Recruiting | 2/3 | 400 | US | Nectero EAST System | Nectero Medical, Inc. | Abdominal Aortic Aneurysm | 03/27 | 12/29 | | |
TAP-DANCE, NCT03942601: Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization |
|
|
| Terminated | 2 | 10 | US | Temsirolimus, Temsirolimus and dexamethasone sodium phosphate | Mercator MedSystems, Inc. | Peripheral Arterial Disease | 04/21 | 04/21 | | |
| Recruiting | N/A | 110 | US, RoW | NEXUS Aortic Stent Graft System | Endospan Ltd. | Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer | 11/24 | 10/29 | | |
| Active, not recruiting | N/A | 260 | Europe, Canada, US, RoW | JETi Peripheral Thrombectomy System | Abbott Medical Devices | Peripheral Artery Thrombosis, Peripheral Venous Thrombosis | 08/24 | 08/25 | | |
| Recruiting | N/A | 300 | US | TREO Abdominal Stent-Graft System | Bolton Medical | Abdominal Aortic Aneurysm | 07/27 | 07/27 | | |
| Dunlevy, Hillary |
| Terminated | 4 | 10 | US | bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Biktarvy, Standard initiation of antiretroviral therapy (ART), Standard of Care ART | University of Colorado, Denver, Gilead Sciences | HIV/AIDS | 07/23 | 07/23 | | |
| Betz, Marian |
| Completed | N/A | 530 | US | Driving Decision Aid, DDA, Older Drivers Website | University of Colorado, Denver, National Institute on Aging (NIA) | Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome | 06/23 | 12/23 | | |
NCT05173922: "Safety in Dementia": An Online Caregiver Intervention |
|
|
| Completed | N/A | 500 | US | Safety in Dementia | University of Colorado, Denver | Caregivers, Decision Making, Alzheimer Disease, Social Media, Safety, Suicide | 10/24 | 10/24 | | |
| Enrolling by invitation | N/A | 27908 | US | Jaspr App | University of Massachusetts, Worcester, Ohio State University, Evidence-Based Practice Institute, Seattle, WA, National Institute of Mental Health (NIMH), Worcester Polytechnic Institute, University of Colorado, Denver | Suicidal Ideation, Suicide Attempt, Self Harm | 06/27 | 06/27 | | |
| Dougherty, Alaina |
| Recruiting | 3 | 132 | US | Shingrix | University of Colorado, Denver | Kidney Transplant Recipient Response to Shingrix Vaccine | 01/26 | 09/26 | | |
| Bukari, Mohammed |
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids |
|
|
| Recruiting | 3 | 150 | Europe, Japan, US, RoW | Ianalumab, VAY736, Eltrombopag, ETB115, Placebo | Novartis Pharmaceuticals | Primary Immune Thrombocytopenia | 08/25 | 05/28 | | |
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 3 | 225 | Europe, Japan, US, RoW | Ianalumab, VAY736, Placebo, Corticosteroids | Novartis Pharmaceuticals | Primary Immune Thrombocytopenia (ITP) | 04/26 | 12/28 | | |
NCT04198623: Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions |
|
|
| Recruiting | 2 | 80 | US | Montelukast 10 Mg Oral Tablet, Singulair | University of California, San Francisco | Infusion Reaction, Monoclonal Antibody | 05/24 | 05/24 | | |
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 64 | US | Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | 02/25 | 02/25 | | |
NCT04905810: Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure |
|
|
| Recruiting | 2 | 20 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Brian Jonas, AbbVie, National Cancer Institute (NCI) | Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | 05/25 | 12/25 | | |
| Scherrer, Sara |
| Terminated | 4 | 10 | US | bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Biktarvy, Standard initiation of antiretroviral therapy (ART), Standard of Care ART | University of Colorado, Denver, Gilead Sciences | HIV/AIDS | 07/23 | 07/23 | | |
| Gisbert, Robyn |
HEART, NCT04790162: Heartfulness Meditation to Improve Resilience Among Health Care Students: A 90 Day Program |
|
|
| Recruiting | N/A | 150 | US | Heartfulness Meditation | University of Colorado, Denver | Mental Health Wellness 1, Stress, Psychological, Depression, Anxiety | 04/24 | 04/24 | | |
| Alfonso, Nicholas |
| Completed | 4 | 20 | US | Vancomycin, Tobramycin | University of Colorado, Denver, Denver Health and Hospital Authority | Fractures, Open, Wounds and Injuries--Infections, Anti-Bacterial Agents, Fractures, Bone, Extremity Fracture Lower, Extremity Fractures Upper | 09/23 | 09/23 | | |
| Onyiah, Joseph |
SIB, NCT04979130: Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 42 | US | Semaglutide, Ozempic, PDS290 pen-injector, Placebo | University of Colorado, Denver, Novo Nordisk A/S | Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability | 12/23 | 12/23 | | |
| Haemer, Matthew A |
NCT05041855: Childhood Obesity Treatment Designed for Low Income and Hispanic Families |
|
|
| Recruiting | N/A | 658 | US | The Healthy Living Program/La Vida Saludable, HeLP, Recommended Treatment of Obesity in Primary Care, RTOP | University of Colorado, Denver, Colorado State University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Pediatric Obesity, Healthy Eating, Physical Activity, Minority Health, Mindfulness, Family, Counseling | 05/26 | 05/27 | | |
| DeLay, Kelli |
NCT05246085: Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids |
|
|
| Recruiting | N/A | 300 | US | Cortisol level | University of Colorado, Denver | Eosinophilic Esophagitis | 07/23 | 07/23 | | |
| Mueller, Raeghan |
| Recruiting | 2/3 | 180 | US | Cannabidiol, Placebo | University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 04/27 | 04/27 | | |
| Completed | 2 | 45 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver | Alcohol Use Disorder | 05/23 | 05/23 | | |
NCT05632627: Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial |
|
|
| Recruiting | 2 | 120 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver, Colorado State University | Brain Injuries, Traumatic | 12/25 | 12/25 | | |
| Recruiting | 2 | 150 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver | Opioid Use Disorder | 02/27 | 02/27 | | |
NCT05822362: CBD for Individuals at Risk for Alzheimer's Disease |
|
|
| Recruiting | 2 | 236 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver | Mild Cognitive Impairment | 04/28 | 04/29 | | |
| Haydek, Chris |
NCT05246085: Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids |
|
|
| Recruiting | N/A | 300 | US | Cortisol level | University of Colorado, Denver | Eosinophilic Esophagitis | 07/23 | 07/23 | | |
| Pessorrusso, Fernanda |
| Recruiting | 3 | 198 | US | GIE Medical ProTractX3 TTS DCB, Control | GIE Medical | Esophageal Stricture | 07/25 | 12/29 | | |
| Recruiting | 3 | 171 | US | GIE Medical ProTractX3 TTS DCB, Control | GIE Medical | Bowel; Stricture | 09/26 | 03/29 | | |
| Active, not recruiting | N/A | 1000 | US | AGBS, Allurion Gastric Balloon System (AGBS) | Allurion Technologies | Obesity | 11/24 | 03/25 | | |
| Laurin, Jaime |
| Recruiting | 2/3 | 180 | US | Cannabidiol, Placebo | University of Colorado, Denver, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 04/27 | 04/27 | | |
NCT05632627: Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial |
|
|
| Recruiting | 2 | 120 | US | Cannabidiol, CBD, Placebo | University of Colorado, Denver, Colorado State University | Brain Injuries, Traumatic | 12/25 | 12/25 | | |
| Moss, Ezra |
| Recruiting | 3 | 132 | US | Shingrix | University of Colorado, Denver | Kidney Transplant Recipient Response to Shingrix Vaccine | 01/26 | 09/26 | | |
| Fullard, Michelle E |
NCT06446505: Evaluation of a Decision Aid for Deep Brain Stimulation Surgery for Parkinson's Disease |
|
|
| Recruiting | N/A | 42 | US | Deep Brain Stimulation Decision Aid | University of Colorado, Denver, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Parkinson Disease | 07/26 | 07/26 | | |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
| Cheung, Stephanie |
NCT04557462 / 2020-002200-40: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
|
|
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | LNP023, iptacopan | Novartis Pharmaceuticals, Novartis Pharma AG | Primary IgA Nephropathy | 10/32 | 10/32 | | |
| Recruiting | N/A | 2000 | US | Sperm Sorting, Sperm Sex Selection | Weill Medical College of Cornell University | Infertility, IVF | 12/26 | 12/27 | | |
